行业洞察美国 FDAT1064
Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
🤖 AI 摘要
The Food and Drug Administration (FDA or Agency) is withdrawing approval of new drug application (NDA) for TAZVERIK (tazemetostat) tablet, 200 milligrams (mg), held by Epizyme, Inc., an Ipsen Company (Epizyme), 1 Main St., Cambridge, MA 02142. Epizyme has voluntarily requested withdrawal of its NDA and has waived the expedited withdrawal procedures.
分析模型：rule-based-v3 · 07-09 06:59
评分详情
综合分 64/100
信源权威
95
影响范围
70
时效性
50
合规紧急
40
行业关注
35
Federal Register: FDA Notices (官方通知)
操作：